Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;51(12):827-34.
doi: 10.1002/dvg.22719. Epub 2013 Nov 21.

Biallelic genome modification in F(0) Xenopus tropicalis embryos using the CRISPR/Cas system

Ira L Blitz  1 , Jacob Biesinger, Xiaohui Xie, Ken W Y Cho
Affiliations

Biallelic genome modification in F(0) Xenopus tropicalis embryos using the CRISPR/Cas system

Ira L Blitz et al. Genesis. 2013 Dec.

Abstract

Gene inactivation is an important tool for correlation of phenotypic and genomic data, allowing researchers to infer normal gene function based on the phenotype when the gene is impaired. New and better approaches are needed to overcome the shortfalls of existing methods for any significant acceleration of scientific progress. We have adapted the CRISPR/Cas system for use in Xenopus tropicalis and report on the efficient creation of mutations in the gene encoding the enzyme tyrosinase, which is responsible for oculocutaneous albinism. Biallelic mutation of this gene was detected in the F0 generation, suggesting targeting efficiencies similar to that of TALENs. We also find that off-target mutagenesis seems to be negligible, and therefore, CRISPR/Cas may be a useful system for creating genome modifications in this important model organism.

Keywords: CRISPR/Cas; TALENs; gene knockouts; gene targeting; zinc finger nucleases.

PubMed Disclaimer

Figures

Figure 1
Figure 1. CRISPR/Cas targeting of the tyrosinase locus in Xenopus tropicalis
A) Cas9-bound gRNA:DNA target region on the tyr gene. The 5'→3' orientation of the transcription unit is from right to left. Overlap with the TALEN binding sites (boxed in yellow) from Ishibashi et al. (2012) is shown. B) Right panel contains examples of stage 41 embryos injected with hCas9 and tyr gRNA. These tadpoles exhibiting typical oculocutaneous albinism found in most of the embryos. A subset retained more pigment but significantly less than wild-type levels (not shown). Left panel is a wild-type control sibling from the same clutch.
Figure 2
Figure 2. The range of albino phenotypes in froglets after targeting tyrosinase
Top left panel: A wild-type frog pigmentation pattern as comparison. The extent of mosaicism is highly variable. Scale bar in lower right panel indicates 1cm.
Figure 3
Figure 3. A catalog of the mutations found in a single albino CRISPR/Cas embryo
The wild-type sequence (parental) is shown at the top. Nineteen PCR product sequences are shown. Red highlighted bases indicate the target site with the PAM sequence in black bold and underlined. The nature of the mutations is indicated in the right column. Δ, deletion; sub, substitutions; WT, wild-type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bassett AR, Tibbit C, Ponting CP, Liu J-L. Highly Efficient Targeted Mutagenesis of Drosophila with the CRISPR/Cas9 System. Cell Reports. 2013;4:220–228. - PMC - PubMed
    1. Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet. 2011;45:273–97. - PubMed
    1. Bibikova M, Carroll D, Segal DJ, Trautman JK, Smith J, Kim YG, Chandrasegaran S. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol. 2001;21:289–97. - PMC - PubMed
    1. Blumberg B, Kang H, Bolado J, Jr., Chen H, Craig AG, Moreno TA, Umesono K, Perlmann T, De Robertis EM, Evans RM. BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes Dev. 1998;12:1269–77. - PMC - PubMed
    1. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326:1509–12. - PubMed

Publication types